ID   GCH1_HUMAN              Reviewed;         250 AA.
AC   P30793; Q6FHY7; Q9Y4I8;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   18-JUN-2025, entry version 233.
DE   RecName: Full=GTP cyclohydrolase 1;
DE            EC=3.5.4.16 {ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916, ECO:0000269|PubMed:3753653};
DE   AltName: Full=GTP cyclohydrolase I;
DE            Short=GTP-CH-I;
GN   Name=GCH1; Synonyms=DYT5, GCH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GCH-1; GCH-2 AND GCH-3).
RC   TISSUE=Liver;
RX   PubMed=1520321; DOI=10.1016/s0006-291x(05)81501-3;
RA   Togari A., Ichinose H., Matsumoto S., Fujita K., Nagatsu T.;
RT   "Multiple mRNA forms of human GTP cyclohydrolase I.";
RL   Biochem. Biophys. Res. Commun. 187:359-365(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GCH-1 AND GCH-2), AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=8068008; DOI=10.1042/bj3020215;
RA   Guetlich M., Jaeger E., Rucknaegel K.P., Werner T., Roedl W., Ziegler I.,
RA   Bacher A.;
RT   "Human GTP cyclohydrolase I: only one out of three cDNA isoforms gives rise
RT   to the active enzyme.";
RL   Biochem. J. 302:215-221(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pheochromocytoma;
RX   PubMed=8695054; DOI=10.1007/bf01271561;
RA   Nomura T., Ohtsuki M., Matsui S., Sumi-Ichinose C., Nomura H., Hagino Y.,
RA   Iwase K., Ichinose H., Fujita K., Nagatsu T.;
RT   "Isolation of a full-length cDNA clone for human GTP cyclohydrolase I type
RT   1 from pheochromocytoma.";
RL   J. Neural Transm. 101:237-242(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GCH-1 AND GCH-4).
RC   TISSUE=Myelomonocyte;
RX   PubMed=11284739; DOI=10.1042/0264-6021:3550499;
RA   Golderer G., Werner E.R., Heufler C., Strohmaier W., Grobner P.,
RA   Werner-Felmayer G.;
RT   "GTP cyclohydrolase I mRNA: novel splice variants in the slime mould
RT   Physarum polycephalum and in human monocytes (THP-1) indicate conservation
RT   of mRNA processing.";
RL   Biochem. J. 355:499-507(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GCH-1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GCH-1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-114.
RC   TISSUE=Granulocyte;
RX   PubMed=8666288; DOI=10.1016/0378-1119(95)00886-1;
RA   Witter K., Werner T., Blusch J.H., Schneider E.-M., Riess O., Ziegler I.,
RA   Roedl W., Bacher A., Guetlich M.;
RT   "Cloning, sequencing and functional studies of the gene encoding human GTP
RT   cyclohydrolase I.";
RL   Gene 171:285-290(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 60-242.
RX   PubMed=1482676; DOI=10.1016/0167-4781(92)90112-d;
RA   Guetlich M., Schott K., Werner T., Bacher A., Ziegler I.;
RT   "Species and tissue specificity of mammalian GTP cyclohydrolase I messenger
RT   RNA.";
RL   Biochim. Biophys. Acta 1171:133-140(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 116-209.
RX   PubMed=7730309; DOI=10.1074/jbc.270.17.10062;
RA   Ichinose H., Ohye T., Matsuda Y., Hori T.A., Blau N., Burlina A., Rouse B.,
RA   Matalon R., Fujita K., Nagatsu T.;
RT   "Characterization of mouse and human GTP cyclohydrolase I genes. Mutations
RT   in patients with GTP cyclohydrolase I deficiency.";
RL   J. Biol. Chem. 270:10062-10071(1995).
RN   [11]
RP   ENZYME ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=3753653; DOI=10.1016/0304-4165(86)90115-7;
RA   Blau N., Niederwieser A.;
RT   "The application of 8-aminoguanosine triphosphate, a new inhibitor of GTP
RT   cyclohydrolase I, to the purification of the enzyme from human liver.";
RL   Biochim. Biophys. Acta 880:26-31(1986).
RN   [12]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=2500984; DOI=10.1016/0300-9084(89)90006-0;
RA   Shen R.-S., Alam A., Zhang Y.X.;
RT   "Human liver GTP cyclohydrolase I: purification and some properties.";
RL   Biochimie 71:343-349(1989).
RN   [13]
RP   ENZYME ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=2463916; DOI=10.1111/j.1432-1033.1989.tb14491.x;
RA   Schoedon G., Redweik U., Curtius H.-C.;
RT   "Purification of GTP cyclohydrolase I from human liver and production of
RT   specific monoclonal antibodies.";
RL   Eur. J. Biochem. 178:627-634(1989).
RN   [14]
RP   INDUCTION.
RX   PubMed=7678411; DOI=10.1016/s0021-9258(18)53931-4;
RA   Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G.,
RA   Schmidt K., Weiss G., Wachter H.;
RT   "Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-
RT   mediated formation of cyclic GMP.";
RL   J. Biol. Chem. 268:1842-1846(1993).
RN   [15]
RP   REVIEW ON VARIANTS.
RX   PubMed=9222755;
RX   DOI=10.1002/(sici)1098-1004(1997)10:1<11::aid-humu2>3.0.co;2-p;
RA   Thoeny B., Blau N.;
RT   "Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin
RT   synthase genes.";
RL   Hum. Mutat. 10:11-20(1997).
RN   [16]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=9445252; DOI=10.1161/01.atv.18.1.27;
RA   Katusic Z.S., Stelter A., Milstien S.;
RT   "Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human
RT   umbilical vein endothelial cells.";
RL   Arterioscler. Thromb. Vasc. Biol. 18:27-32(1998).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12176133; DOI=10.1016/s0008-6363(02)00460-1;
RA   Cai S., Alp N.J., McDonald D., Smith I., Kay J., Canevari L., Heales S.,
RA   Channon K.M.;
RT   "GTP cyclohydrolase I gene transfer augments intracellular
RT   tetrahydrobiopterin in human endothelial cells: effects on nitric oxide
RT   synthase activity, protein levels and dimerisation.";
RL   Cardiovasc. Res. 55:838-849(2002).
RN   [18]
RP   INDUCTION.
RX   PubMed=12002810; DOI=10.1016/s0024-3205(02)01503-5;
RA   Ohtsuki M., Shiraishi H., Kato T., Kuroda R., Tazawa M., Sumi-Ichinose C.,
RA   Tada S., Udagawa Y., Itoh M., Hishida H., Ichinose H., Nagatsu T.,
RA   Hagino Y., Nomura T.;
RT   "cAMP inhibits cytokine-induced biosynthesis of tetrahydrobiopterin in
RT   human umbilical vein endothelial cells.";
RL   Life Sci. 70:2187-2198(2002).
RN   [19]
RP   INDUCTION.
RX   PubMed=12607127; DOI=10.1007/s00395-003-0394-y;
RA   Gesierich A., Niroomand F., Tiefenbacher C.P.;
RT   "Role of human GTP cyclohydrolase I and its regulatory protein in
RT   tetrahydrobiopterin metabolism.";
RL   Basic Res. Cardiol. 98:69-75(2003).
RN   [20]
RP   INDUCTION.
RX   PubMed=14646243; DOI=10.1254/jphs.93.265;
RA   Shiraishi H., Kato T., Atsuta K., Sumi-Ichinose C., Ohtsuki M., Itoh M.,
RA   Hishida H., Tada S., Udagawa Y., Nagatsu T., Hagino Y., Ichinose H.,
RA   Nomura T.;
RT   "cGMP inhibits GTP cyclohydrolase I activity and biosynthesis of
RT   tetrahydrobiopterin in human umbilical vein endothelial cells.";
RL   J. Pharmacol. Sci. 93:265-271(2003).
RN   [21]
RP   ACTIVITY REGULATION.
RX   PubMed=14717702; DOI=10.1046/j.1432-1033.2003.03933.x;
RA   Suzuki T., Kurita H., Ichinose H.;
RT   "GTP cyclohydrolase I utilizes metal-free GTP as its substrate.";
RL   Eur. J. Biochem. 271:349-355(2004).
RN   [22]
RP   FUNCTION.
RX   PubMed=16338639; DOI=10.1016/j.brainresprot.2005.10.005;
RA   Duan C.-L., Su Y., Zhao C.-L., Lu L.-L., Xu Q.-Y., Yang H.;
RT   "The assays of activities and function of TH, AADC, and GCH1 and their
RT   potential use in ex vivo gene therapy of PD.";
RL   Brain Res. Brain Res. Protoc. 16:37-43(2005).
RN   [23]
RP   INDUCTION.
RX   PubMed=15604419; DOI=10.1161/01.res.0000153669.24827.df;
RA   Huang A., Zhang Y.-Y., Chen K., Hatakeyama K., Keaney J.F. Jr.;
RT   "Cytokine-stimulated GTP cyclohydrolase I expression in endothelial cells
RT   requires coordinated activation of nuclear factor-kappaB and Stat1/Stat3.";
RL   Circ. Res. 96:164-171(2005).
RN   [24]
RP   INDUCTION.
RX   PubMed=15649650; DOI=10.1016/j.freeradbiomed.2004.11.004;
RA   Kalivendi S., Hatakeyama K., Whitsett J., Konorev E., Kalyanaraman B.,
RA   Vasquez-Vivar J.;
RT   "Changes in tetrahydrobiopterin levels in endothelial cells and adult
RT   cardiomyocytes induced by LPS and hydrogen peroxide -- a role for GFRP?";
RL   Free Radic. Biol. Med. 38:481-491(2005).
RN   [25]
RP   SUBUNIT.
RX   PubMed=16848765; DOI=10.1042/bj20060765;
RA   Pandya M.J., Golderer G., Werner E.R., Werner-Felmayer G.;
RT   "Interaction of human GTP cyclohydrolase I with its splice variants.";
RL   Biochem. J. 400:75-80(2006).
RN   [26]
RP   ENZYME ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=16778797; DOI=10.1038/sj.jid.5700425;
RA   Chavan B., Gillbro J.M., Rokos H., Schallreuter K.U.;
RT   "GTP cyclohydrolase feedback regulatory protein controls cofactor 6-
RT   tetrahydrobiopterin synthesis in the cytosol and in the nucleus of
RT   epidermal keratinocytes and melanocytes.";
RL   J. Invest. Dermatol. 126:2481-2489(2006).
RN   [27]
RP   INTERACTION WITH AHSA1 AND GCHFR.
RX   PubMed=16696853; DOI=10.1111/j.1471-4159.2006.03836.x;
RA   Swick L., Kapatos G.;
RT   "A yeast 2-hybrid analysis of human GTP cyclohydrolase I protein
RT   interactions.";
RL   J. Neurochem. 97:1447-1455(2006).
RN   [28]
RP   FUNCTION.
RX   PubMed=17057711; DOI=10.1038/nm1490;
RA   Tegeder I., Costigan M., Griffin R.S., Abele A., Belfer I., Schmidt H.,
RA   Ehnert C., Nejim J., Marian C., Scholz J., Wu T., Allchorne A.,
RA   Diatchenko L., Binshtok A.M., Goldman D., Adolph J., Sama S., Atlas S.J.,
RA   Carlezon W.A., Parsegian A., Loetsch J., Fillingim R.B., Maixner W.,
RA   Geisslinger G., Max M.B., Woolf C.J.;
RT   "GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and
RT   persistence.";
RL   Nat. Med. 12:1269-1277(2006).
RN   [29]
RP   PHOSPHORYLATION AT SER-81.
RX   PubMed=17704208; DOI=10.1161/circresaha.107.153809;
RA   Widder J.D., Chen W., Li L., Dikalov S., Thony B., Hatakeyama K.,
RA   Harrison D.G.;
RT   "Regulation of tetrahydrobiopterin biosynthesis by shear stress.";
RL   Circ. Res. 101:830-838(2007).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 55-250, SUBUNIT, AND ZINC-BINDING
RP   SITES.
RX   PubMed=11087827; DOI=10.1073/pnas.240463497;
RA   Auerbach G., Herrmann A., Bracher A., Bader G., Gutlich M., Fischer M.,
RA   Neukamm M., Garrido-Franco M., Richardson J., Nar H., Huber R., Bacher A.;
RT   "Zinc plays a key role in human and bacterial GTP cyclohydrolase I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:13567-13572(2000).
RN   [32]
RP   VARIANTS DRD TRP-88; VAL-134 AND GLU-201.
RX   PubMed=7874165; DOI=10.1038/ng1194-236;
RA   Ichinose H., Ohye T., Takahashi E., Seki N., Hori T., Segawa M., Nomura Y.,
RA   Endo K., Tanaka H., Tsuji S., Fujita K., Nagatsu T.;
RT   "Hereditary progressive dystonia with marked diurnal fluctuation caused by
RT   mutations in the GTP cyclohydrolase I gene.";
RL   Nat. Genet. 8:236-242(1994).
RN   [33]
RP   VARIANT DRD PRO-79, AND VARIANTS HPABH4B HIS-184 AND ILE-211.
RX   PubMed=7501255; DOI=10.1016/0304-3940(95)11820-m;
RA   Ichinose H., Ohye T., Segawa M., Nomura Y., Endo K., Tanaka H., Tsuji S.,
RA   Fujita K., Nagatsu T.;
RT   "GTP cyclohydrolase I gene in hereditary progressive dystonia with marked
RT   diurnal fluctuation.";
RL   Neurosci. Lett. 196:5-8(1995).
RN   [34]
RP   VARIANT DRD PRO-144.
RX   PubMed=8957022; DOI=10.1002/ana.410400517;
RA   Hirano M., Tamaru Y., Ito H., Matsumoto S., Imai T., Ueno S.;
RT   "Mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive
RT   dystonia onset.";
RL   Ann. Neurol. 40:796-798(1996).
RN   [35]
RP   VARIANTS DRD PRO-88; PRO-153; ARG-203; ARG-224 AND SER-234.
RX   PubMed=8852666; DOI=10.1093/hmg/5.3.403;
RA   Bandmann O., Nygaard T.G., Surtess R., Mardsen C.D., Wood N.W.,
RA   Harding A.E.;
RT   "Dopa-responsive dystonia in British patients: new mutations of the GTP-
RT   cyclohydrolase I gene and evidence for genetic heterogeneity.";
RL   Hum. Mol. Genet. 5:403-406(1996).
RN   [36]
RP   VARIANT DRD SER-178.
RX   PubMed=9120469; DOI=10.1136/jnnp.62.4.420;
RA   Beyer K., Lao-Villadoniga J.I., Vecino-Bilbao B., Cacabelos R.,
RA   de la Fuent-Fernandez R.;
RT   "A novel point mutation in the GTP cyclohydrolase I gene in a Spanish
RT   family with hereditary progressive and dopa responsive dystonia.";
RL   J. Neurol. Neurosurg. Psych. 62:420-421(1997).
RN   [37]
RP   VARIANTS DRD LEU-23 AND ASN-115.
RX   PubMed=9328244; DOI=10.1136/jnnp.63.3.304;
RA   Jarman P.R., Bandmann O., Marsden C.D., Wood N.W.;
RT   "GTP cyclohydrolase I mutations in patients with dystonia responsive to
RT   anticholinergic drugs.";
RL   J. Neurol. Neurosurg. Psych. 63:304-308(1997).
RN   [38]
RP   VARIANTS HPABH4B ASP-108; THR-221 AND ARG-224.
RX   PubMed=9667588; DOI=10.1002/ana.410440107;
RA   Furukawa Y., Kish S.J., Bebin E.M., Jacobson R.D., Fryburg J.S.,
RA   Wilson W.G., Shimadzu M., Hyland K., Trugman J.M.;
RT   "Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase
RT   I gene mutations.";
RL   Ann. Neurol. 44:10-16(1998).
RN   [39]
RP   VARIANTS DRD GLN-71; VAL-74; ALA-83; ILE-191; VAL-211 AND TRP-241.
RX   PubMed=9778264; DOI=10.1002/ana.410440411;
RA   Bandmann O., Valente E.M., Holmans P., Surtees R.A., Walters J.H.,
RA   Wevers R.A., Marsden C.D., Wood N.W.;
RT   "Dopa-responsive dystonia: a clinical and molecular genetic study.";
RL   Ann. Neurol. 44:649-656(1998).
RN   [40]
RP   VARIANT DRD SER-249.
RX   PubMed=10987649; DOI=10.1007/s004390051093;
RA   Hwu W.-L., Wang P.-J., Hsiao K.-J., Wang T.-R., Chiou Y.-W., Lee Y.-M.;
RT   "Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I
RT   mutation.";
RL   Hum. Genet. 105:226-230(1999).
RN   [41]
RP   VARIANTS DRD ARG-102; LYS-102; ARG-141; TRP-141; THR-176; SER-178 AND
RP   LYS-186.
RX   PubMed=10582612; DOI=10.1046/j.1471-4159.1999.0732510.x;
RA   Suzuki T., Ohye T., Inagaki H., Nagatsu T., Ichinose H.;
RT   "Characterization of wild-type and mutants of recombinant human GTP
RT   cyclohydrolase I: relationship to etiology of dopa-responsive dystonia.";
RL   J. Neurochem. 73:2510-2516(1999).
RN   [42]
RP   VARIANT DRD LYS-135.
RX   PubMed=10208576; DOI=10.1097/00001756-199902250-00008;
RA   Brique S., Destee A., Lambert J.-C., Mouroux V., Delacourte A., Amouyel P.,
RA   Chartier-Harlin M.-C.;
RT   "A new GTP-cyclohydrolase I mutation in an unusual dopa-responsive
RT   dystonia, familial form.";
RL   NeuroReport 10:487-491(1999).
RN   [43]
RP   VARIANT DRD VAL-90.
RX   PubMed=10076897; DOI=10.1016/s0304-3940(98)00984-7;
RA   Hirano M., Komure O., Ueno S.;
RT   "A novel missense mutant inactivates GTP cyclohydrolase I in dopa-
RT   responsive dystonia.";
RL   Neurosci. Lett. 260:181-184(1999).
RN   [44]
RP   VARIANTS DRD ALA-83; 88-ARG-GLN-89 DEL; SER-178; ARG-180; LEU-199 AND
RP   GLU-201.
RX   PubMed=10825351; DOI=10.1093/brain/123.6.1112;
RA   Tassin J., Duerr A., Bonnet A.-M., Gil R., Vidailhet M., Luecking C.B.,
RA   Goas J.-Y., Durif F., Abada M., Echenne B., Motte J., Lagueny A.,
RA   Lacomblez L., Jedynak P., Bartholome B., Agid Y., Brice A.;
RT   "Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?";
RL   Brain 123:1112-1121(2000).
RN   [45]
RP   VARIANTS DRD ARG-163 AND VAL-213.
RX   PubMed=11113234; DOI=10.1212/wnl.55.11.1735;
RA   Steinberger D., Korinthenberg R., Topka H., Berghaeuser M., Wedde R.,
RA   Mueller U.;
RT   "Dopa-responsive dystonia: mutation analysis of GCH1 and analysis of
RT   therapeutic doses of L-dopa. German Dystonia Study Group.";
RL   Neurology 55:1735-1737(2000).
RN   [46]
RP   VARIANT DRD ARG-224.
RX   PubMed=12391354; DOI=10.1212/wnl.59.8.1241;
RA   Leuzzi V., Carducci C., Carducci C., Cardona F., Artiola C., Antonozzi I.;
RT   "Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive
RT   myoclonus-dystonia syndrome.";
RL   Neurology 59:1241-1243(2002).
RN   [47]
RP   VARIANT DRD ILE-106.
RX   PubMed=17101830; DOI=10.1001/archneur.63.11.1605;
RA   Ohta E., Funayama M., Ichinose H., Toyoshima I., Urano F., Matsuo M.,
RA   Tomoko N., Yukihiko K., Yoshino S., Yokoyama H., Shimazu H., Maeda K.,
RA   Hasegawa K., Obata F.;
RT   "Novel mutations in the guanosine triphosphate cyclohydrolase 1 gene
RT   associated with DYT5 dystonia.";
RL   Arch. Neurol. 63:1605-1610(2006).
RN   [48]
RP   VARIANTS CYS-75; VAL-98 AND THR-135.
RX   PubMed=23762320; DOI=10.1371/journal.pone.0065215;
RA   Cai C., Shi W., Zeng Z., Zhang M., Ling C., Chen L., Cai C., Zhang B.,
RA   Li W.D.;
RT   "GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in familial
RT   and sporadic dopa-responsive dystonia patients.";
RL   PLoS ONE 8:E65215-E65215(2013).
CC   -!- FUNCTION: Positively regulates nitric oxide synthesis in umbilical vein
CC       endothelial cells (HUVECs). May be involved in dopamine synthesis. May
CC       modify pain sensitivity and persistence. Isoform GCH-1 is the
CC       functional enzyme, the potential function of the enzymatically inactive
CC       isoforms remains unknown. {ECO:0000269|PubMed:12176133,
CC       ECO:0000269|PubMed:16338639, ECO:0000269|PubMed:17057711,
CC       ECO:0000269|PubMed:8068008, ECO:0000269|PubMed:9445252}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + H2O = 7,8-dihydroneopterin 3'-triphosphate + formate +
CC         H(+); Xref=Rhea:RHEA:17473, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:37565, ChEBI:CHEBI:58462; EC=3.5.4.16;
CC         Evidence={ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916,
CC         ECO:0000269|PubMed:3753653};
CC   -!- ACTIVITY REGULATION: GTP shows a positive allosteric effect, and
CC       tetrahydrobiopterin inhibits the enzyme activity. Zinc is required for
CC       catalytic activity. Inhibited by Mg(2+). {ECO:0000269|PubMed:14717702,
CC       ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:3753653}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=116 uM for GTP {ECO:0000269|PubMed:2500984};
CC       pH dependence:
CC         Optimum pH is 7.7 in phosphate buffer. {ECO:0000269|PubMed:2500984};
CC       Temperature dependence:
CC         Relatively stable at high temperatures. Retains 50% of its activity
CC         after incubation at 70 degrees Celsius for 15 minutes.
CC         {ECO:0000269|PubMed:2500984};
CC   -!- PATHWAY: Cofactor biosynthesis; 7,8-dihydroneopterin triphosphate
CC       biosynthesis; 7,8-dihydroneopterin triphosphate from GTP: step 1/1.
CC       {ECO:0000305|PubMed:16778797, ECO:0000305|PubMed:2463916,
CC       ECO:0000305|PubMed:3753653}.
CC   -!- SUBUNIT: Toroid-shaped homodecamer, composed of a dimer of pentamers.
CC       The inactive isoforms also form decamers and may possibly be
CC       incorporated into GCH1 heterodecamers, decreasing enzyme stability and
CC       activity. Interacts with AHSA1 and GCHFR/GFRP.
CC       {ECO:0000269|PubMed:11087827, ECO:0000269|PubMed:16696853,
CC       ECO:0000269|PubMed:16848765}.
CC   -!- INTERACTION:
CC       P30793; O95433: AHSA1; NbExp=3; IntAct=EBI-958183, EBI-448610;
CC       P30793; O14787-2: TNPO2; NbExp=3; IntAct=EBI-958183, EBI-12076664;
CC       P30793; Q9Y5L0: TNPO3; NbExp=3; IntAct=EBI-958183, EBI-1042571;
CC       P30793; P63104: YWHAZ; NbExp=4; IntAct=EBI-958183, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12176133,
CC       ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916}. Nucleus
CC       {ECO:0000269|PubMed:16778797}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=GCH-1;
CC         IsoId=P30793-1; Sequence=Displayed;
CC       Name=GCH-2;
CC         IsoId=P30793-2; Sequence=VSP_001612, VSP_001613;
CC       Name=GCH-3;
CC         IsoId=P30793-3; Sequence=VSP_001610;
CC       Name=GCH-4;
CC         IsoId=P30793-4; Sequence=VSP_001611, VSP_001614;
CC   -!- TISSUE SPECIFICITY: In epidermis, expressed predominantly in basal
CC       undifferentiated keratinocytes and in some but not all melanocytes (at
CC       protein level). {ECO:0000269|PubMed:16778797}.
CC   -!- INDUCTION: Up-regulated by IFNG/IFN-gamma, TNF, IL1B/interleukin-1
CC       beta, bacterial lipopolysaccharides (LPS) and phenylalanine, and down-
CC       regulated by dibutyryl-cAMP, iloprost and 8-bromo-cGMP in HUVEC cells.
CC       Up-regulation of GCH1 expression, in turn, stimulates production of
CC       tetrahydrobiopterin, with subsequent elevation of endothelial nitric
CC       oxide synthase activity. Cytokine-induced GCH1 up-regulation in HUVECs
CC       in response to TNF and IFNG/IFN-gamma involves cooperative activation
CC       of both the NF-kappa-B and JAK2/STAT pathways. Also up-regulated by
CC       hydrogen peroxide in human aorta endothelial cells (HAECs).
CC       {ECO:0000269|PubMed:12002810, ECO:0000269|PubMed:12607127,
CC       ECO:0000269|PubMed:14646243, ECO:0000269|PubMed:15604419,
CC       ECO:0000269|PubMed:15649650, ECO:0000269|PubMed:7678411,
CC       ECO:0000269|PubMed:9445252}.
CC   -!- PTM: Phosphorylated by casein kinase II at Ser-81 in HAECs during
CC       oscillatory shear stress; phosphorylation at Ser-81 results in
CC       increased enzyme activity. {ECO:0000269|PubMed:17704208}.
CC   -!- DISEASE: Hyperphenylalaninemia, BH4-deficient, B (HPABH4B)
CC       [MIM:233910]: A disease characterized by malignant
CC       hyperphenylalaninemia due to tetrahydrobiopterin deficiency, and
CC       defective neurotransmission due to depletion of the neurotransmitters
CC       dopamine and serotonin. The principal symptoms include: psychomotor
CC       retardation, tonicity disorders, convulsions, drowsiness, irritability,
CC       abnormal movements, hyperthermia, hypersalivation, and difficulty
CC       swallowing. Some patients may present a phenotype of intermediate
CC       severity between severe hyperphenylalaninemia and mild dystonia. In
CC       this intermediate phenotype, there is marked motor delay, but no
CC       intellectual disability and only minimal, if any,
CC       hyperphenylalaninemia. {ECO:0000269|PubMed:7501255,
CC       ECO:0000269|PubMed:9667588}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Dystonia, dopa-responsive (DRD) [MIM:128230]: A form of
CC       dystonia that responds to L-DOPA treatment without side effects.
CC       Dystonia is defined by the presence of sustained involuntary muscle
CC       contractions, often leading to abnormal postures. DRD typically
CC       presents in childhood with walking problems due to dystonia of the
CC       lower limbs and worsening of the dystonia towards the evening. It is
CC       characterized by postural and motor disturbances showing marked diurnal
CC       fluctuation. Torsion of the trunk is unusual. Symptoms are alleviated
CC       after sleep and aggravated by fatigue and exercise.
CC       {ECO:0000269|PubMed:10076897, ECO:0000269|PubMed:10208576,
CC       ECO:0000269|PubMed:10582612, ECO:0000269|PubMed:10825351,
CC       ECO:0000269|PubMed:10987649, ECO:0000269|PubMed:11113234,
CC       ECO:0000269|PubMed:12391354, ECO:0000269|PubMed:17101830,
CC       ECO:0000269|PubMed:7501255, ECO:0000269|PubMed:7874165,
CC       ECO:0000269|PubMed:8852666, ECO:0000269|PubMed:8957022,
CC       ECO:0000269|PubMed:9120469, ECO:0000269|PubMed:9328244,
CC       ECO:0000269|PubMed:9778264}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the GTP cyclohydrolase I family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S44049; AAB23164.1; -; mRNA.
DR   EMBL; S44053; AAB23165.1; -; mRNA.
DR   EMBL; S43856; AAB23166.1; -; mRNA.
DR   EMBL; Z29433; CAB77391.1; -; mRNA.
DR   EMBL; Z29434; CAB77392.1; -; mRNA.
DR   EMBL; U19523; AAB16861.1; -; mRNA.
DR   EMBL; U66095; AAD38866.1; -; mRNA.
DR   EMBL; U66097; AAD38868.1; -; mRNA.
DR   EMBL; CR536551; CAG38788.1; -; mRNA.
DR   EMBL; CH471061; EAW80647.1; -; Genomic_DNA.
DR   EMBL; BC025415; AAH25415.1; -; mRNA.
DR   EMBL; L29478; AAB42186.1; -; Genomic_DNA.
DR   EMBL; Z30952; CAA83213.1; -; Genomic_DNA.
DR   EMBL; Z16418; CAA78908.1; -; mRNA.
DR   EMBL; U19259; AAB60633.1; -; Genomic_DNA.
DR   EMBL; U19256; AAB60633.1; JOINED; Genomic_DNA.
DR   EMBL; U19257; AAB60633.1; JOINED; Genomic_DNA.
DR   EMBL; U19258; AAB60633.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS41954.1; -. [P30793-4]
DR   CCDS; CCDS45110.1; -. [P30793-2]
DR   CCDS; CCDS9720.1; -. [P30793-1]
DR   PIR; G01630; PC1117.
DR   PIR; JC1225; JC1225.
DR   RefSeq; NP_000152.1; NM_000161.3. [P30793-1]
DR   RefSeq; NP_001019195.1; NM_001024024.2. [P30793-1]
DR   RefSeq; NP_001019241.1; NM_001024070.2. [P30793-4]
DR   RefSeq; NP_001019242.1; NM_001024071.2. [P30793-2]
DR   PDB; 1FB1; X-ray; 3.10 A; A/B/C/D/E=55-250.
DR   PDB; 6Z80; EM; 3.00 A; A/B/C/D/E/F/G/H/I/J=41-250.
DR   PDB; 6Z85; EM; 2.90 A; A/B/C/D/E/F/G/H/I/J=41-250.
DR   PDB; 6Z86; X-ray; 2.21 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T=41-250.
DR   PDB; 6Z87; X-ray; 2.56 A; A/B/C/D/E=41-250.
DR   PDB; 6Z88; X-ray; 2.69 A; A/B/C/D/E/F/G/H/I/J=41-250.
DR   PDB; 6Z89; X-ray; 2.37 A; A/B/C/D/E=41-250.
DR   PDB; 7ALA; X-ray; 1.85 A; A/B/C/D/E=42-250.
DR   PDB; 7ALB; X-ray; 1.98 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T=42-250.
DR   PDB; 7ALC; X-ray; 1.73 A; A/B/C/D/E=42-250.
DR   PDB; 7ALQ; X-ray; 2.21 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T=42-250.
DR   PDBsum; 1FB1; -.
DR   PDBsum; 6Z80; -.
DR   PDBsum; 6Z85; -.
DR   PDBsum; 6Z86; -.
DR   PDBsum; 6Z87; -.
DR   PDBsum; 6Z88; -.
DR   PDBsum; 6Z89; -.
DR   PDBsum; 7ALA; -.
DR   PDBsum; 7ALB; -.
DR   PDBsum; 7ALC; -.
DR   PDBsum; 7ALQ; -.
DR   AlphaFoldDB; P30793; -.
DR   EMDB; EMD-11113; -.
DR   EMDB; EMD-11114; -.
DR   SMR; P30793; -.
DR   BioGRID; 108913; 68.
DR   FunCoup; P30793; 849.
DR   IntAct; P30793; 45.
DR   MINT; P30793; -.
DR   STRING; 9606.ENSP00000477796; -.
DR   DrugBank; DB02377; Guanine.
DR   DrugBank; DB04137; Guanosine-5'-Triphosphate.
DR   DrugBank; DB02325; Isopropyl alcohol.
DR   iPTMnet; P30793; -.
DR   PhosphoSitePlus; P30793; -.
DR   BioMuta; GCH1; -.
DR   DMDM; 399536; -.
DR   jPOST; P30793; -.
DR   MassIVE; P30793; -.
DR   PaxDb; 9606-ENSP00000419045; -.
DR   PeptideAtlas; P30793; -.
DR   ProteomicsDB; 54735; -. [P30793-1]
DR   ProteomicsDB; 54736; -. [P30793-2]
DR   ProteomicsDB; 54737; -. [P30793-3]
DR   ProteomicsDB; 54738; -. [P30793-4]
DR   Pumba; P30793; -.
DR   Antibodypedia; 23963; 378 antibodies from 34 providers.
DR   DNASU; 2643; -.
DR   Ensembl; ENST00000395514.5; ENSP00000378890.1; ENSG00000131979.20. [P30793-1]
DR   Ensembl; ENST00000491895.7; ENSP00000419045.2; ENSG00000131979.20. [P30793-1]
DR   Ensembl; ENST00000536224.2; ENSP00000445246.2; ENSG00000131979.20. [P30793-2]
DR   Ensembl; ENST00000543643.6; ENSP00000444011.2; ENSG00000131979.20. [P30793-4]
DR   GeneID; 2643; -.
DR   KEGG; hsa:2643; -.
DR   MANE-Select; ENST00000491895.7; ENSP00000419045.2; NM_000161.3; NP_000152.1.
DR   UCSC; uc001xbh.2; human. [P30793-1]
DR   AGR; HGNC:4193; -.
DR   CTD; 2643; -.
DR   DisGeNET; 2643; -.
DR   GeneCards; GCH1; -.
DR   GeneReviews; GCH1; -.
DR   HGNC; HGNC:4193; GCH1.
DR   HPA; ENSG00000131979; Tissue enhanced (bone marrow, liver).
DR   MalaCards; GCH1; -.
DR   MIM; 128230; phenotype.
DR   MIM; 233910; phenotype.
DR   MIM; 600225; gene.
DR   OpenTargets; ENSG00000131979; -.
DR   Orphanet; 98808; Autosomal dominant dopa-responsive dystonia.
DR   Orphanet; 2102; GTP cyclohydrolase I deficiency.
DR   VEuPathDB; HostDB:ENSG00000131979; -.
DR   eggNOG; KOG2698; Eukaryota.
DR   GeneTree; ENSGT00390000013481; -.
DR   HOGENOM; CLU_049768_1_3_1; -.
DR   InParanoid; P30793; -.
DR   OMA; CEHMCMS; -.
DR   OrthoDB; 4966at2759; -.
DR   PAN-GO; P30793; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; P30793; -.
DR   BioCyc; MetaCyc:HS05586-MONOMER; -.
DR   BRENDA; 3.5.4.16; 2681.
DR   PathwayCommons; P30793; -.
DR   Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   SABIO-RK; P30793; -.
DR   SignaLink; P30793; -.
DR   SIGNOR; P30793; -.
DR   UniPathway; UPA00848; UER00151.
DR   BioGRID-ORCS; 2643; 15 hits in 1174 CRISPR screens.
DR   ChiTaRS; GCH1; human.
DR   EvolutionaryTrace; P30793; -.
DR   GeneWiki; GTP_cyclohydrolase_I; -.
DR   GenomeRNAi; 2643; -.
DR   Pharos; P30793; Tbio.
DR   PRO; PR:P30793; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P30793; protein.
DR   Bgee; ENSG00000131979; Expressed in secondary oocyte and 184 other cell types or tissues.
DR   ExpressionAtlas; P30793; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0044306; C:neuron projection terminus; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003934; F:GTP cyclohydrolase I activity; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0042416; P:dopamine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0050884; P:neuromuscular process controlling posture; IMP:MGI.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0010460; P:positive regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0042559; P:pteridine-containing compound biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:UniProtKB.
DR   GO; GO:0014916; P:regulation of lung blood pressure; IEA:Ensembl.
DR   GO; GO:2000121; P:regulation of removal of superoxide radicals; IMP:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0048265; P:response to pain; ISS:UniProtKB.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0034341; P:response to type II interferon; IDA:UniProtKB.
DR   GO; GO:0006729; P:tetrahydrobiopterin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0046654; P:tetrahydrofolate biosynthetic process; IEA:InterPro.
DR   CDD; cd00642; GTP_cyclohydro1; 1.
DR   FunFam; 1.10.286.10:FF:000003; GTP cyclohydrolase 1; 1.
DR   FunFam; 3.30.1130.10:FF:000012; GTP cyclohydrolase 1; 1.
DR   Gene3D; 1.10.286.10; -; 1.
DR   Gene3D; 3.30.1130.10; -; 1.
DR   HAMAP; MF_00223; FolE; 1.
DR   InterPro; IPR043133; GTP-CH-I_C/QueF.
DR   InterPro; IPR043134; GTP-CH-I_N.
DR   InterPro; IPR001474; GTP_CycHdrlase_I.
DR   InterPro; IPR018234; GTP_CycHdrlase_I_CS.
DR   InterPro; IPR020602; GTP_CycHdrlase_I_dom.
DR   NCBIfam; TIGR00063; folE; 1.
DR   NCBIfam; NF006825; PRK09347.1-2; 1.
DR   NCBIfam; NF006826; PRK09347.1-3; 1.
DR   PANTHER; PTHR11109:SF11; GTP CYCLOHYDROLASE 1; 1.
DR   PANTHER; PTHR11109; GTP CYCLOHYDROLASE I; 1.
DR   Pfam; PF01227; GTP_cyclohydroI; 1.
DR   SUPFAM; SSF55620; Tetrahydrobiopterin biosynthesis enzymes-like; 1.
DR   PROSITE; PS00859; GTP_CYCLOHYDROL_1_1; 1.
DR   PROSITE; PS00860; GTP_CYCLOHYDROL_1_2; 1.
DR   neXtProt; NX_P30793; -.
DR   PharmGKB; PA28608; -.
DR   TreeFam; TF105616; -.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing; Cytoplasm;
KW   Disease variant; Dystonia; GTP-binding; Hydrolase; Metal-binding;
KW   Nucleotide-binding; Nucleus; Parkinsonism; Phenylketonuria; Phosphoprotein;
KW   Proteomics identification; Reference proteome;
KW   Tetrahydrobiopterin biosynthesis; Zinc.
FT   CHAIN           1..250
FT                   /note="GTP cyclohydrolase 1"
FT                   /id="PRO_0000119478"
FT   REGION          1..64
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..14
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        35..44
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         141
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:11087827"
FT   BINDING         144
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:11087827"
FT   BINDING         212
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:11087827"
FT   MOD_RES         60
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         81
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17704208"
FT   VAR_SEQ         210..250
FT                   /note="Missing (in isoform GCH-3)"
FT                   /evidence="ECO:0000303|PubMed:1520321"
FT                   /id="VSP_001610"
FT   VAR_SEQ         210..233
FT                   /note="HMCMVMRGVQKMNSKTVTSTMLGV -> KSNKYNKGLSPLLSSCHLFVAILK
FT                   (in isoform GCH-4)"
FT                   /evidence="ECO:0000303|PubMed:11284739"
FT                   /id="VSP_001611"
FT   VAR_SEQ         210..213
FT                   /note="HMCM -> SAEP (in isoform GCH-2)"
FT                   /evidence="ECO:0000303|PubMed:1520321,
FT                   ECO:0000303|PubMed:8068008"
FT                   /id="VSP_001612"
FT   VAR_SEQ         214..250
FT                   /note="Missing (in isoform GCH-2)"
FT                   /evidence="ECO:0000303|PubMed:1520321,
FT                   ECO:0000303|PubMed:8068008"
FT                   /id="VSP_001613"
FT   VAR_SEQ         234..250
FT                   /note="Missing (in isoform GCH-4)"
FT                   /evidence="ECO:0000303|PubMed:11284739"
FT                   /id="VSP_001614"
FT   VARIANT         15
FT                   /note="G -> D (in HGCH-3)"
FT                   /id="VAR_002632"
FT   VARIANT         23
FT                   /note="P -> L (in DRD; dbSNP:rs41298432)"
FT                   /evidence="ECO:0000269|PubMed:9328244"
FT                   /id="VAR_002633"
FT   VARIANT         71
FT                   /note="L -> Q (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:9778264"
FT                   /id="VAR_016888"
FT   VARIANT         74
FT                   /note="A -> V (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:9778264"
FT                   /id="VAR_016889"
FT   VARIANT         75
FT                   /note="Y -> C (found in patients with DRD; uncertain
FT                   significance)"
FT                   /id="VAR_072733"
FT   VARIANT         79
FT                   /note="L -> P (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:7501255"
FT                   /id="VAR_002634"
FT   VARIANT         83
FT                   /note="G -> A (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10825351,
FT                   ECO:0000269|PubMed:9778264"
FT                   /id="VAR_016890"
FT   VARIANT         88..89
FT                   /note="Missing (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10825351"
FT                   /id="VAR_016891"
FT   VARIANT         88
FT                   /note="R -> P (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:8852666"
FT                   /id="VAR_002635"
FT   VARIANT         88
FT                   /note="R -> W (in DRD; dbSNP:rs104894433)"
FT                   /evidence="ECO:0000269|PubMed:7874165"
FT                   /id="VAR_002636"
FT   VARIANT         90
FT                   /note="G -> V (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10076897"
FT                   /id="VAR_016892"
FT   VARIANT         98
FT                   /note="A -> V"
FT                   /id="VAR_072734"
FT   VARIANT         102
FT                   /note="M -> K (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10582612"
FT                   /id="VAR_002637"
FT   VARIANT         102
FT                   /note="M -> R (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10582612"
FT                   /id="VAR_016893"
FT   VARIANT         106
FT                   /note="T -> I (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:17101830"
FT                   /id="VAR_054112"
FT   VARIANT         108
FT                   /note="G -> D (in HPABH4B; intermediate phenotype
FT                   presenting with dystonia and motor delay;
FT                   dbSNP:rs104894435)"
FT                   /evidence="ECO:0000269|PubMed:9667588"
FT                   /id="VAR_016894"
FT   VARIANT         115
FT                   /note="D -> N (in DRD; dbSNP:rs1393095176)"
FT                   /evidence="ECO:0000269|PubMed:9328244"
FT                   /id="VAR_016895"
FT   VARIANT         134
FT                   /note="D -> V (in DRD; dbSNP:rs104894437)"
FT                   /evidence="ECO:0000269|PubMed:7874165"
FT                   /id="VAR_002638"
FT   VARIANT         135
FT                   /note="I -> K (in DRD; dbSNP:rs104894441)"
FT                   /evidence="ECO:0000269|PubMed:10208576"
FT                   /id="VAR_016896"
FT   VARIANT         135
FT                   /note="I -> T"
FT                   /id="VAR_072735"
FT   VARIANT         141
FT                   /note="C -> R (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10582612"
FT                   /id="VAR_016897"
FT   VARIANT         141
FT                   /note="C -> W (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10582612"
FT                   /id="VAR_002639"
FT   VARIANT         144
FT                   /note="H -> P (in DRD; dbSNP:rs104894440)"
FT                   /evidence="ECO:0000269|PubMed:8957022"
FT                   /id="VAR_002640"
FT   VARIANT         153
FT                   /note="H -> P (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:8852666"
FT                   /id="VAR_002641"
FT   VARIANT         163
FT                   /note="L -> R (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:11113234"
FT                   /id="VAR_016898"
FT   VARIANT         176
FT                   /note="S -> T (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10582612"
FT                   /id="VAR_016899"
FT   VARIANT         178
FT                   /note="R -> S (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10582612,
FT                   ECO:0000269|PubMed:10825351, ECO:0000269|PubMed:9120469"
FT                   /id="VAR_002642"
FT   VARIANT         180
FT                   /note="Q -> R (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10825351"
FT                   /id="VAR_016900"
FT   VARIANT         184
FT                   /note="R -> H (in HPABH4B; severe hyperphenylalaninemia;
FT                   dbSNP:rs104894445)"
FT                   /evidence="ECO:0000269|PubMed:7501255"
FT                   /id="VAR_002643"
FT   VARIANT         186
FT                   /note="T -> K (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10582612"
FT                   /id="VAR_002644"
FT   VARIANT         191
FT                   /note="V -> I (in DRD; dbSNP:rs762208304)"
FT                   /evidence="ECO:0000269|PubMed:9778264"
FT                   /id="VAR_016901"
FT   VARIANT         199
FT                   /note="P -> L (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:10825351"
FT                   /id="VAR_016902"
FT   VARIANT         201
FT                   /note="G -> E (in DRD; dbSNP:rs104894438)"
FT                   /evidence="ECO:0000269|PubMed:10825351,
FT                   ECO:0000269|PubMed:7874165"
FT                   /id="VAR_002645"
FT   VARIANT         203
FT                   /note="G -> R (in DRD; dbSNP:rs988395114)"
FT                   /evidence="ECO:0000269|PubMed:8852666"
FT                   /id="VAR_002646"
FT   VARIANT         211
FT                   /note="M -> I (in HPABH4B; severe hyperphenylalaninemia;
FT                   dbSNP:rs104894443)"
FT                   /evidence="ECO:0000269|PubMed:7501255"
FT                   /id="VAR_002647"
FT   VARIANT         211
FT                   /note="M -> V (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:9778264"
FT                   /id="VAR_016903"
FT   VARIANT         213
FT                   /note="M -> V (in DRD; dbSNP:rs1348562494)"
FT                   /evidence="ECO:0000269|PubMed:11113234"
FT                   /id="VAR_016904"
FT   VARIANT         221
FT                   /note="M -> T (in HPABH4B; intermediate phenotype
FT                   presenting with dystonia and motor delay;
FT                   dbSNP:rs104894434)"
FT                   /evidence="ECO:0000269|PubMed:9667588"
FT                   /id="VAR_016905"
FT   VARIANT         224
FT                   /note="K -> R (in HPABH4B and DRD; phenotype presenting
FT                   with dystonia and myoclonus; dbSNP:rs41298442)"
FT                   /evidence="ECO:0000269|PubMed:12391354,
FT                   ECO:0000269|PubMed:8852666, ECO:0000269|PubMed:9667588"
FT                   /id="VAR_002648"
FT   VARIANT         234
FT                   /note="F -> S (in DRD)"
FT                   /evidence="ECO:0000269|PubMed:8852666"
FT                   /id="VAR_002649"
FT   VARIANT         241
FT                   /note="R -> W (in DRD; dbSNP:rs1375209791)"
FT                   /evidence="ECO:0000269|PubMed:9778264"
FT                   /id="VAR_016906"
FT   VARIANT         249
FT                   /note="R -> S (in DRD; dbSNP:rs104894442)"
FT                   /evidence="ECO:0000269|PubMed:10987649"
FT                   /id="VAR_016907"
FT   CONFLICT        11
FT                   /note="E -> G (in Ref. 4; AAD38866)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        206
FT                   /note="V -> I (in Ref. 9; CAA78908)"
FT                   /evidence="ECO:0000305"
FT   HELIX           61..81
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   STRAND          86..88
FT                   /evidence="ECO:0007829|PDB:6Z85"
FT   HELIX           89..91
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           94..105
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           107..110
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           113..116
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   TURN            117..119
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   STRAND          121..123
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   STRAND          129..141
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   TURN            142..144
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   STRAND          147..157
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   STRAND          159..163
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           165..176
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   STRAND          177..180
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           182..197
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   STRAND          200..210
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           211..213
FT                   /evidence="ECO:0007829|PDB:7ALB"
FT   TURN            215..217
FT                   /evidence="ECO:0007829|PDB:1FB1"
FT   STRAND          224..232
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           233..236
FT                   /evidence="ECO:0007829|PDB:7ALC"
FT   HELIX           238..247
FT                   /evidence="ECO:0007829|PDB:7ALC"
SQ   SEQUENCE   250 AA;  27903 MW;  B8A0CB344C598B9A CRC64;
     MEKGPVRAPA EKPRGARCSN GFPERDPPRP GPSRPAEKPP RPEAKSAQPA DGWKGERPRS
     EEDNELNLPN LAAAYSSILS SLGENPQRQG LLKTPWRAAS AMQFFTKGYQ ETISDVLNDA
     IFDEDHDEMV IVKDIDMFSM CEHHLVPFVG KVHIGYLPNK QVLGLSKLAR IVEIYSRRLQ
     VQERLTKQIA VAITEALRPA GVGVVVEATH MCMVMRGVQK MNSKTVTSTM LGVFREDPKT
     REEFLTLIRS
//
